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ABSTRACT 
PURPOSE 
Up to 60% of people with epilepsy (PwE) have psychiatric comorbidity including anxiety. 
Anxiety remains under recognized in PwE. This study investigates if screening tools validated 
for depression could be used to detect anxiety disorders in PWE. Additionally it analyses the 
effect of anxiety on QoL. 
METHODS 
261 participants with a confirmed diagnosis of epilepsy were included. Neurological 
Disorders Depression Inventory for Epilepsy (NDDI-E) and Emotional Thermometers (ET), 
both validated to screen for depression were used. Hospital Anxiety and Depression Scale-
Anxiety (HADS-A) with a cut off for moderate and severe anxiety was used as the reference 
standard. QoL was measured with EQ5-D. Sensitivity, specificity, positive and negative 
predictive value and ROC analysis as well as multivariate regression analysis were performed.  
RESULTS 
Patients with depression (n=46) were excluded as multivariate regression analysis showed 
that depression was the only significant determinant of having anxiety in the group. Against 
HADS-A,  NDDI-E and ET-7 showed highest level of accuracy in recognizing anxiety with 
ET7 being the most effective tool. QoL was significantly reduced in PwE and anxiety.  
CONCLUSIONS 
Our study showed that reliable screening for moderate to severe anxiety in PwE without co-
morbid depression is feasible with screening tools for depression. The cut off values for 
anxiety are different from those for depression in ET7 but very similar in NDDI-E. ET7 can 
be applied to screen simultaneously for depression and “pure” anxiety. Anxiety reduces 
significantly QoL. We recommend screening as an initial first step to rule out patients who are 
unlikely to have anxiety.
Highlights 
 Moderate to severe anxiety is a frequent comorbidity in epilepsy, in our cohort 
prevalence was 26,4% 
 Depression was the only significant determinant for anxiety, prevalence of anxiety in 
non-depressed PwE was 15,8%. 
 Screening for anxiety independent from depression can be achieved with the ET7 tool. 
 Quality of life was significantly reduced in PwE and anxiety, independent of 
depression.  
 Significant reduction in QoL in PwE and anxiety was not only in subdomains of 
anxiety/depression, but also pain and activities. 
 
BACKGROUND 
Epilepsy is a debilitating disorder not just due to the occurrence of seizures. People with 
epilepsy (PwE) suffer a range of comorbid conditions which may have a negative impact on 
quality of life (QoL). QoL of PwE may be affected by several factors. The sudden, often 
unpredictable occurrence of seizures is a major factor as well as the stigma of the disease
1
. 
Restrictions on normal activities, resulting in low self-esteem and social rejection are also 
unfavorable consequences. These factors in this relatively young patient group can themselves 
contribute to psychiatric disturbances, as well as biological factors. Numerous studies show 
that the incidence of psychiatric disorders in PwE is significantly higher than in the general 
population
2-7
. Up to 50 or 60% of patients with chronic epilepsy have at least one mood 
disorder including depression and anxiety
8
. Prevalence studies on the association between 
epilepsy and psychiatric disorders have found that epilepsy can precede, co-occur with or 
follow the diagnosis of a psychiatric disorder
9
.  
 
Anxiety disorders (AnxD) are the second most prevalent psychiatric disorder in people with 
epilepsy, mostly commonly a generalized interictal AnxD affecting between 10-25% 
8,9,10
. 
These clinical characteristics were recently confirmed in a study of a specialist 
neuropsychiatry service for PWE, where 27% suffered from generalized anxiety 
11
. AnxD, as 
other psychiatric comorbidities, are however often under recognized and undertreated in 
PwE
6
, but can significantly affect QoL. In one study, AnxD or major depressive episode 
(MDE) had a comparable negative impact on quality of life measured with the Quality of Life 
in Epilepsy Inventory-89 (QOLIE-89) while comorbid occurrence of both mood and anxiety 
disorders yielded a worse impact
12
. In another study of 154 outpatient adults with epilepsy, 
presence of anxiety symptoms was the most important factor in explaining a worse QoL
13
. 
Although it has not yet been systematically demonstrated that the treatment of anxiety 
improves QoL in PWE, effective strategies in the general population are well established. As 
for depression, a first step achieving this in epilepsy must surely be to ensure those who might 
benefit are more easily identified when attending epilepsy outpatients‟ clinics. A range of 
tools have been developed and validated for detection of depression in PwE by ourselves and 
others
14,15
. In the present paper we investigate whether a range of traditional and visual 
analogue depression screening tools are also effective in detecting anxiety disorders. 
Additionally, we investigate QoL in PwE with and without anxiety. 
 
METHODS 
Sample 
The patients‟ selection and characteristics are described elsewhere15. To summarize, we 
enrolled consecutive participants at the epilepsy outpatient service at Atkinson Morley 
Neurosciences Centre in South West London. Subjects were asked to complete selected 
screening tools for depression and anxiety disorders, including Major Depression Inventory 
(MDI), Hospital Anxiety and Depression Score (HADS), Neurological Disorders Depression 
Inventory for Epilepsy (NDDI-E), the Quality of Life Questionnaire (EQ-5D-3L), revised 
Emotional Thermometers (ET7) prior to or immediately afterwards their clinical consultation. 
In the present study, we used HADS-A as gold standard to detect anxiety.  ICD-10 diagnosis 
of depression was detected by MDI questionnaire. All examinations and analysis were in 
accordance with the Declaration of Helsinki (2008). As per Research Ethic Committee (REC) 
advice, research limited to secondary use of anonymized information previously collected in 
the course of normal care is excluded from formal REC review.  
 
Inclusion/Exclusion criteria 
Epilepsy was diagnosed in all subjects by a neurologist with special interest in epilepsy. The 
diagnosis and specific epilepsy syndrome were confirmed from reviewing the clinical notes. 
Incomplete questionnaire samples were excluded from analysis. Our records were examined 
to ensure that the data of the same individual was not repeatedly entered in the analysis.  
 
Conventional verbal tools 
Hospital Anxiety and Depression Scale (HADS) 
The HADS was originally designed as a screening tool for depression and anxiety in hospital 
outpatient clinics
16. 
More recently, it was validated in primary care and in the community, 
with the advantage of a completion time of 2–5 min17. HADS consists of seven questions for 
depression and seven for anxiety, scored on a 4 item Linkert scale. Score for each subscale 
(anxiety and depression) can range from 0-21 with HADS scores categorized as follows: 
normal (0-7), mild (8-10), moderate (11-14), severe (15-21). Scores for the entire scale 
(emotional distress) range from 0-42, with higher scores indicating more distress. Snaith 
recommends a cut off of >7 for both HADS-D (the depression subscale) and HADS-A (the 
anxiety subscale), while combined total scores (HADS-T) can also be used
17
.  
 
Definition of HADS-A defined anxiety in this sample  
Screening in hospital outpatient clinics for anxiety aims at identifying a clinical relevant 
anxiety. We therefore decided to choose the cut off for moderate anxiety to differentiate 
anxiety. Moderate and severe anxiety is more likely to have therapeutic relevance then mild 
anxiety. Hence, dichotomization of the HADS-A anxiety variable was done as “anxiety 
positive (+) with cutoff of >10 and anxiety negative (-)  with cutoff ≤10”.  
 
Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) 
This screening tool for depression in PwE consists of six statements about thoughts and 
feelings in the preceding two weeks that are scored on a 4 item Linkert scale resulting in a 
minimum score of 6 and maximum of 24. It takes less than 3 min to complete
18
. It was has 
been validated in a US population (ideal cutoff of >14) and in a UK population (ideal cut off 
of >15), resulting in 90%/87% specificity and 81%/81% sensitivity against DSM-IV major 
depression with high NPV of 0.96/0.97 and rather moderate PPV of 0.62/0.51 respectively
14, 
15
. 
 
 
Visual analog tool 
Revised Emotional Thermometers (ET7)  
ET7 is shown in Figure 1. It consists of seven visual analogue scales, which take less than 2 
minutes to complete and there is no need to score afterwards. The seven different scales allow 
individual as well as combined analysis. It has been validated to screen for depression in PwE, 
resulting in a sensitivity of 85% and specificity of 79%. The NPV was 0.96 and PPV 0.47 for 
the combined tool
15
. This tool has been used previously with a lower number of scales (ET4, 
ET5) to detect depression in oncology and cardiology settings against a DSM-IV diagnosis of 
depression
19, 20
.  
 
[Insert Fig 1 here] 
 
 
EQ-5D-3L: 
Quality of Life was measured using 5 questions from EQ-5D and a visual analogue scale (EQ-
VAS).  
EQ5D is a descriptive system, which records the current health status and the subjective 
perception of quality of life. It is a form of questionnaire divided into 5 dimensions (mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression). The intensity of disability 
in each range should be stated as none (0), moderate (1), severe (2). Furthermore, it records 
the patients‟ self-rated health on a vertical visual analogue scale (EQ-VAS). It is ranged from 
0 (the worst possible health status) to 100 (the best possible health status)
21
.  
 
Statistical Analysis 
Accuracy measures 
There are various measures that incorporate both sensitivity and specificity to describe the 
validity of screening or diagnostic tests. These include positive and negative predictive values 
(PPVs and NPVs),  the area under receiver operating characteristic (ROC) curves, positive 
utility index (UI+), negative utility index (UI).  Clinical utility measures the clinical value of a 
screening test by combining its ability to identify cases and to discriminate non-cases. UI+ is 
calculated as sensitivity×positive predictive value while UI is calculated as 
specificity×negative predictive value. UI+ shows how well the tool identifies a diagnosis 
when present and UI shows how well the tool excludes a diagnosis when absent
20
. 
ROC curve analysis was performed to create area under the curve (AUC) scores for the 
various tools against the diagnosis of anxiety. This analysis was used to calculate the optimal 
cutoff scores for maximizing sensitivity and specificity of the tools. PPVs, NPVs, UI+ and 
UI˗ were calculated. Further measures of diagnostic accuracy were recorded including 
Youden J (sensitivity + specificity) ˗1). 
Performance of the tests was taken as follows: <0.2 poor, 0.2–0.4 fair, 0.4–0.6 moderate, 0.6–
0.8 good, >0.8 very good. Conventionally AUC scores >0.8 are said to be good and >0.9 
excellent. 
 
Reliability measures  
Internal consistency was reported using the Cronbach alpha (CA) estimate using standardized 
variables. CA estimates the proportion of variance in the test scores that can be attributed to 
true score variance. So it is used to estimate the proportion of variance that is systematic or 
consistent in a set of test scores. It can range from 00.0 (if no variance is consistent) to 1.00 (if 
all variance is consistent) with all values between 00.0 and 1.00 also being possible. Scores 
are interpreted as follows: ≥0.7 = reasonable, ≥0.8 = good, ≥0.9 = excellent reliability.  
 
Relationship measures 
The relationships between the dependent and independent variables were analyzed using the 
non-parametric chi-square test (when both variables were categorical), Student‟s T-test (when 
one variable was categorical and the other one was continuous) and Mann-Whitney-U (when 
the distribution was not homogenous in T-test).  
The correlation between anxiety and quality of life was analyzed by using a standardized 
regression coefficient. Graphical illustration was accomplished by scatter plots.  
Further the effect of anxiety on quality of life was demonstrated separately for each domain of 
EQ-5D.  
Multivariable analysis is a statistical tool for determining the unique contributions of various 
factors to a single event or outcome
22
. It is an accepted statistical method for assessing 
association between an antecedent characteristic (risk factor) and a quantal outcome 
(probability of disease occurrence), statistically adjusting for potential confounding effects of 
other covariates
23
. 
We performed a multivariate analysis to show the significant determinants of having HADS-
A defined anxiety in the sample. 
 
 
RESULTS 
Descriptive statistics and demographics of the study population are given in Table 1.  
 
[Insert Table 1 here] 
 
In our sample of 261 patients, the prevalence of depression (Dep) was 17.6% (n=46) and 
anxiety (Anx) was 26.4% (n=69). There was a higher proportion of women in PwE with 
anxiety as compared to PwE without anxiety but this wasn‟t stastically significant.  
Of the 46 patients with depression 76% (n=35) had moderate or severe anxiety according to 
HADS-A. There was a significant overlap noted between anxiety and depression with over 
half of PwE with anxiety also showing depression. Hence, prevalence of anxiety in the non-
depressed group was 15.8% (34 out of 215).  
 
Multivariate analysis  
Multivariate regression analysis showed “presence of depression” according to “ICD-10 
defined depression” was the only variable having a statistically significant effect on the 
presence of HADS-A anxiety (table 2).  
 
[Insert Table 2 here] 
 
Correlation of anxiety and QoL 
In view of this relationship, the correlation of anxiety (ET-A as well as HADS-A) and quality 
of life (EQ-VAS) was analyzed with all patients including those with depression (n=261) and 
in a group excluding all patients with depression (n=215).  
Simple regression showed for both samples a statistically significant negative correlation 
between EQ-VAS score and HADS-A/ET-A. The lower the EQ-VAS was stated, the higher 
was the scoring for HADS-A and ET-A (p<= 0,001). Scatter plots for the two groups are 
demonstrated side by side in Figure 2.  
 
[Insert Figure 2 here] 
 
The EQ-5D-3L was only fulfilled by 258 patients (Anx- n=191, Anx+ n=67).  It was found 
that a larger proportion of patients with anxiety rated themselves more impaired in various 
domaines of EQ-5D QoL-Scale than patients without anxiety.  
The same could be stated after exclusion of patients with depression. Based on all patients 
(n=258) a statistical significance was stated in EQ (Anx/Dep), EQ (Pain) and EQ (Activities). 
After extracting depressed patients EQ (Anx/Dep) showed a statistical significance only.  
Figure 3 shows the impairment of quality of life by EQ-5D domains compared in three 
groups, PwE with depression, PwE without depression but anxiety, and PwE without 
depression and without anxiety. 
 
[Insert Figure 3 here] 
 
 
Performance of screening tools  
We have used ROC curve analysis to identify the optimal cutoff for anxiety for each tool in 
this sample. Equally patients with depression (n=46) were excluded for the evaluation of 
using depression screening tools for detection of anxiety.  
For the conventional verbal tool, the NDDI-E, the optimal cutoff for our sample was 14 
versus 15. For the visual analogue scales, the ET7, we compared the results for the five 
individual thermometers: distress (DT), anger (AngT), depression (DepT), anxiety (AnxT), 
and need for help (HelpT) as well as sum scores for both the ET4 (excluding the HelpT) and 
the ET7 tool. Overall, ET4 had an optimal cutoff of 12 vs 13 and ET7 of 21 vs 22. The 
optimal cut offs for the subscales of both tools are shown in detail in Table 3. 
 
[Insert Table 3 here] 
 
Reliability 
The overall reliability of both, the ET7 and NDDI-E was good, although the former was 
slightly superior to the latter (α =0.894, 95% lower confidence limit [CL] 0.871 vs α =0.836, 
95% lower confidence limit [CL] 0.799).  
DISCUSSION 
We showed with a multivariate logistic regression analysis that ICD-10 defined depression 
was the only statistically significant factor affecting the presence of AnxD. In fact it is 
highlighting the complex overlap between the two conditions. Our sample showed that 
moderate to severe anxiety was more prevalent than depression. Three quarters of PWE who 
had depression also had anxiety whereas only half of PWE who had anxiety had co-morbid 
depression. This means not only is anxiety more common overall, there are more PWE who 
have “pure” anxiety than “pure” depression highlighting importance of recognition of anxiety 
in PWE.  
Moreover our findings demonstrate that the presence of anxiety, according to HADS-A and 
ET-A, is associated with a significant impairment of QoL. Equally the influence of anxiety 
could be shown after excluding the patients with depression, which implies anxiety as an 
independent factor on QoL.  
 
As NDDI-E and ET7 are validated for screening depression, cut offs for anxiety were 
identified in a sample without depression to avoid confounding effects. After excluding 
patients with depression we focused in the analysis on the non-depressed sample (n=215). 34 
(15.8%) patients had anxiety according to HADS-A (cutoff >10). Gaitatzis et al
9
 had found 
that prevalence of anxiety disorders in PwE was 10-25% and our sample‟s percentage was 
consistent with the literature. A Canadian population-based study showed a lifetime 
prevalence of any AnxD in PwE of 22.8% (vs 11% in non-epilepsy subjects).  AnxD and DD 
tend to occur together with a high frequency, and, in the Canadian study, a lifetime prevalence 
of 34.2% was found for comorbid AnxD and DD in PwE (vs 19.6% in non-epilepsy 
subjects)
6
. Again, our findings are in line with previously reported data. Whereas anxiety in 
the healthy population is more prevalent in women, previous studies in PwE showed that there 
is no such difference
22,24 
. Although in our study slightly more women were screened positive 
for anxiety, the difference was not statistically significant, which is in line with the previously 
reported findings. 
  
We defined having anxiety as “positive” grouping moderate and severe anxiety together 
(HADS-A >10=anxiety(+)) while we took the mild anxiety group into the “anxiety negative” 
ones. This was to differentiate the group who would likely require treatment for anxiety. The 
most accurate scales by ROC area were NDDI-E and ET7 and the Anxiety Thermometer 
(AnxT) as single item (Table-3). ET7 showed a slightly superior reliability. Cut off values for 
detecting anxiety were very close to those detecting depression in NDDI-E (14 vs 15 for 
anxiety and 15 vs 16 for depression) and identical in AnxT (5 vs 6 for anxiety and 5 vs 6 for 
depression). In contrast ET7 showed a clear distinction for cut off levels detecting anxiety (21 
vs 22) and depression (28 vs 29) i.e. a score between 22 and 28 identifies PwE who may 
suffer “pure” anxiety but not depression. 
 
In the present study QoL is measured by a different scale than in previous studies
12, 24,  25
, but 
yields the same conclusions showing  the effect of anxiety on QoL in PWE is robust.  
Interestingly, after removing all depressed patients, PwE and anxiety showed no more 
physical complains in the QoL domains but low QoL in view of depression/anxiety. This is in 
line with our previous observation that PwE and depression report more somatic symptoms 
27, 
28
 . 
 Similar to depression, anxiety is often missed as comorbidity in PwE 
12
. Given that anxiety 
and depression in PwE respond well to pharmacological treatments or cognitive behavioral 
therapy and that anxiety in PwE significantly worsens QoL and health care costs, neurologists 
are urged to start identifying and treating this comorbidity 
12, 26.
   
  
Screening tools can support the clinician in daily practice to identify a condition, in the 
present study comorbidity of anxiety in PwE. The ideal tool should reliably identify the 
condition as a „„rule-in‟‟ or „„case-finding‟‟ tool. Alternatively screening tools can support by 
identifying subjects who are not suffering from the condition, i.e. working as a “rule-out” 
tool. In the present study the screening tools didn‟t perform well in a „case finding role‟, but 
several items performed well as a “rule out” tool due to the high negative predictive value and 
specificity. In this role, the most effective tool was the ET7 having NPV= 0.964, specificity = 
0.757, ROC area = 0.882. Using these accuracy levels and a point prevalence of HADS-A 
anxiety of 15.8%, ET7 would help exclude anxiety in 64 of 85 non-anxiety patients with 3 
PwE with anxiety being missed (false negative), and correctly identify 12 of 15 cases with 
anxiety with 21 false positives.  The high number of false positives reflects the relatively low 
PPV of approximately 0.4.  We have to stress at this point that screening tools do not diagnose 
and treatment should never be started purely on the basis of a positive result on screening. 
This illustrates rather the usefulness of this screening tool, guiding the clinician to a group of 
patients where further questions about potential AnxD should be applied. Post screening 
clinical enquiry to clarify the diagnosis or referral to an appropriate professional such as a 
neuropsychiatrist would be recommended. 
Both screening tools are simple to apply and take only 2-3 minutes to complete. The visual 
analogue scales are easier to score for the clinician and may be less dependent on language 
skills particularly in a multicultural setting or in people with learning disability. However, the 
latter statement is an assumption our sample size was too small to support this statistically. 
Our data support ET7 as the only tool which allows to screen for depression and 
independently for “pure” anxiety in PwE.  
 
Limitations 
As mentioned in our previous study on screening for depression, our subject population may 
not have a true representation of the demographic spread of the clinic population because of 
the number of exclusions we were forced to make on the grounds of poor English language 
skills, in particular among the middle aged and elderly Asian population. We attempted to 
include consecutive attendees, but some refusals and exclusions may have compromised our 
findings, and we do not have data of those who were excluded 
15
. However the data represents 
a routine clinical practice and hence has high clinical applicability. 
We have used HADS-A to be a gold standard a likelihood of the diagnosis of anxiety in this 
sample. However, HADS-A was originally designed to be used as a screening instrument for 
use with outpatients attending medical clinics 
16
. Future replication of this work with a more 
robust gold standard of anxiety such as structured clinical interviews would be recommended. 
 
CONCLUSION 
Anxiety is an important health problem in epilepsy patients and it has attainable and simple 
means of detection and treatment.  
Our intention was to validate if the depression screening tools for use in epilepsy outpatients 
are identifying anxiety as well. As the screening tools are designed to be given to patients 
prior to the clinic appointment, results should be available at the consultation. Our results 
indicate that ET7 allows screening for depression and “pure” anxiety independently. 
Furthermore we have shown that anxiety has a significant impact on QoL measure with the 
EQ-5D-3L independent of depression. 
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Tables and Figure legends 
 
Table1. Characteristics of the patients data and it's relation to anxiety (HADS-A) 
 All cases 
 
 
N=261 
Anxiety (+) according to HADS-A 
(>10) 
N=69 
Anxiety (-) according to HADS-A 
(≤10) 
N=192 
P 
value 
Age,mean,(standard 
deviation) 
39,8 (15,2) 39,9 
(14,3) 
39,8 
(15,6) 
0,74 
Gender,female, n (%) 153 
(58,6%) 
44 
(63,7%) 
109 
(56,7%) 
0,31 
Epilepsy type: 
Focal, n (%) 
159 
(60,9%) 
44 
(63,7%) 
115 
(59,8%) 
0,57 
Epilepsy type: 
Generalised, n (%) 
86 
(32,9%) 
21 
(30,4%) 
65 
(33,8%) 
0,60 
Epilepsy type: 
Unclassified, n (%) 
16 
(6,1%) 
4 
(5,7%) 
12 
(6,25%) 
0,89 
Depression (+)  
(MDI-ICD-10) , n (%) 
46 
(17,6%) 
35 
(50,7%) 
11 
(5,7%) 
<0,001 
*p≤0.05, statistically significant 
 
Table 2. The parameters of the multivariate logistic regression model for anxiety (+) and 
levels of significance 
 B SE Wald df Sig Exp(B) 95% CI for 
Exp(B) 
lower 
95% CI for 
Exp(B) 
upper 
Depression (+) 
 (MDI-ICD-10) 
2,830 0,393 51,850 1 0,000 16,939 7,841 36,590 
Constant -1,672 0,187 80,032 1 0,000 0,188   
*p≤0.05, statistically significant 
 
Table 3. Accuracy and utility of tools to identify HADS-A defined anxiety episode 
(>10=anxiety(+)) in epilepsy patients (n=215) without depression according to MDI ICD-10. 
Scores for the complete screening tools are marked in grey. ET4 includes of the first four 
mentioned subscales. 
  Directional accuracy Overall accuracy   
Test 
 
Optimal 
cutoff 
 
SN SP PPV NPV ROC area 
(95% CI) 
Youden Fraction 
correct 
 
Clinical 
utility 
İndex (+) 
Clinical 
utility 
İndex 
(-) 
NNDI-E  
14 vs 15 0.735 0.862 0.500 0.945 
0.874  
(0.806-0.941) 
0.597 0.841 0.367 0.814 
NDDI-E 
Q1 
2 vs 3 0.824 0.630 0.294 0.950 
0.778  
(0.695-0.861) 
0.454 0.660 0.242 0.598 
NDDI-E 
Q2 
2 vs 3 0.676 0.812 0.403 0.930 
0.782  
(0.698-0.866) 
0.488 0.790 0.272 0.755 
NDDI-E 
Q3 
2 vs 3 0.588 0.702 0.270 0.900 
0.701  
(0.605-0.797) 
0.290 0.683 0.158 0.631 
NDDI-E 
Q4 
1 vs 2  0.647 0.867 0.478 0.928 
0.765  
(0.664-0.866) 
0.514 0.832 0.309 0.849 
NDDI-E 3 vs 4 0.500 0.917 0.531 0.967 0.783  0.417 0.902 0.265 0.886 
Q5 (0.699-0.867) 
NDDI-E 
Q6 
2 vs 3 0.676 0.751 0.338 0.925 
0.768  
(0.680-0.855) 
0.427 0.739 0.228 0.694 
ET7 
21 vs 22 0.853 0.757 0.397 0.964 
0.882  
(0.827-0.938) 
0.610 0.772 0.338 0.729 
ET4 
12 vs 13 0.882 0.685 0.344 0.968 
0.866  
(0.809-0.923) 
0.567 0.716 0.303 0.663 
DistT 
2 vs 3 0.824 0.652 0.307 0.951 
0.800  
(0.727-0.872) 
0.476 0.679 0.252 0.620 
AnxT 
5 vs 6 0.765 0.862 0.509 0.951 
0.866  
(0.803-0.929) 
0.627 0.846 0.389 0.819 
DepT 
2 vs 3 0.853 0.691 0.337 0.961 
0.826  
(0.753-0.900) 
0.544 0.711 0.287 0.664 
AngT 
3 vs 4 0.765 0.713 0.320 0.940 
0.779  
(0.693-0.864) 
0.478 0.706 0.244 0.670 
DurT 
4 vs 5 0.735 0.757 0.362 0.938 
0.796  
(0.719-0.874) 
0.492 0.753 0.266 0.710 
BurT 
1 vs 2 0.853 0.740 0.381 0.964 
0.843  
(0.766-0.920) 
0.593 0.758 0.324 0.713 
HelpT 
1 vs 2 0.824 0.696 0.337 0.954 
0.779  
(0.715-0.883) 
0.536 0.716 0.277 0.663 
SN, sensitivity; SP, specificity; PPV, positive predictive value; NPV, negative predictive value; TP, true positive; TN, true negative; FP, false 
positive; FN, false 
negative. 
Fraction correct (overall accuracy) = TP + TN/TP + TN + FP + FN 
*p≤0.05, statistically significant 
 
Figure 1. Revised Emotional Thermometers (ET7). The following instruction was given: In 
the first four columns, please mark the number (0-10) that best describes how much emotional 
upset you have been experiencing in the past two weeks, including today. In the next three 
columns please indicate how much impact this has had on you, how long you have been 
experiencing these emotional problems and how much you need help for these.  
 
Figure 2. Simple regression showed negative correlation of QoL and Anxiety in both groups 
– anxiety with (left) and without (right) depression. Upper chart for comparison to HADS 
score, lower chart comparing to emotional thermometer anxiety. 
 
Figure 3: Impairment of QoL according to the EQ-5D domains in PwE. It shows the results 
of PwE with depression and anxiety (blue) compared with PwE with anxiety but no 
depression (orange) and PwE with neither depression nor anxiety. Activities and pain are 
statistically significant relevant for reduction of QoL as is feeling of anxiety and depression in 
PwE with anxiety independent from depression. 
statistically significant *p≤0.05, ** p≤0,01, *** p≤0,001  
 
 



